Kevin Shaw, MD

• Advanced Cardiac Life Support Provider
• National Board of Medical Examiners
• Utah Physician and Surgeon License
• Drug Enforcement Agency
• California Physician and Surgeon License
• American Board of Internal Medicine Internal Medicine
• Fluoroscopy Supervisor and Operator License
• American Board of Internal Medicine, Pulmonary Disease
• American Board of Internal Medicine, Critical Care Medicine

Professional Memberships

Publications

Presentations

1. American College of Physicians Utah Chapter, Clinical Vignette Competition 2006, Runner-Up. An Unusual Insulinoma Case.
2. American Thoracic Society International Conference 2009. A Novel Assay to Investigate Ion Transport Across Mouse Airway Epithelium.
3. North American Cystic Fibrosis Conference 2009. Evidence of ΔF508 CFTR Activity in the Intact Native Lower Airways of the CF Mouse.
4. UCSD Summer Critical Care Conference 2010. Advanced Modes of Ventilation.
5. California Thoracic Society 2011. 75 y.o. Female with Dry Cough.
6. Rady Children’s Hospital Cystic Fibrosis Family Education Day 2012. Transition to the Adult Clinic.
7. Topics & Advances in Pulmonary and Critical Care Medicine 2013. Ultrasound-Guided Central Line Placement, Hands-on Simulation Session.
8. Rady Children’s Hospital Bioethics Education Program 2013. A Transition Too Late: Efforts at the End of Life.
9. American Thoracic Society Resident Boot Camp 2014. Airway Management 101.
10. UCSD Heart/Lung Transplant Conference 2014. Cystic Fibrosis and Lung Transplant.
11. Rady Children’s Hospital Cystic Fibrosis Staff Education Day 2014. Cystic Fibrosis and Transition.

• Laboratory Technician, 1997-1999, University of California San Diego. Principal Investigator Jeffrey Esko, Ph.D. Assisted with multiple research projects, with responsibilities including screening a cDNA library, cloning, sequencing, plasmid construction, and initiation of a yeast 2-hybrid system to investigate Golgi apparatus protein interactions.
• Research Fellow in Pulmonary and Critical Care Medicine, 2008-2010, University of California San Diego. Principal Investigator Paul Quinton, Ph.D. Our project included determination of electrolyte transport properties in the intact lower murine airways. We developed a novel assay which uses perfused ex-vivo murine lungs, in an attempt to better replicate in-vivo conditions than is possible with cell culture models. Specific topics of investigation included the roles of CFTR and the calcium-activated chloride channel, comparing both wild type and ΔF508 cystic fibrosis mice.
• A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV1 greater than or equal to 75% but less than or equal to 110% Predicted TIGER-2 (Inspire 08-110) Amendment 1 / Co-PI HRPP #081213 Closed 4/25/11
• Protocol Title: Study 08-114: Open-label Extension of Study 08-110, A Multi- Center Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease Amendment: January 20, 2010 (Inspire Tiger 2 Open Label Study) / Co-PI HRPP #101101 Closed 5/5/11
• Clofazimine for single patient use. / PI HRPP #101879 Closed 8/12/11
• A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis PTC-124-GD-009-CF; Protocol Version 2 / Co-PI HRPP #091065 Closed 4/10/12
• A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (AeroquinTM) Versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis; Study Number: MPEX-209 / PI HRPP #110852
• A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of MP-376 (Levofloxacin Inhalation Solution; AeroquinTM) in Stable Cystic Fibrosis Patients; Study Number: MPEX 207 / Co-PI HRPP #110431
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Subjects with Cystic Fibrosis; Study Number: GS-US-205-0170 / PI HRPP #121356
• A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors; Study Number: CFFC-OB-11 / PI HRPP #121086
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation; Study Number: VX12-809-103 / Sub-PI HRPP #130404
• A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation; Study Number: VX12-809-102 / PI HRPP #131206
• A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation; Study Number: VX12-809-105 / Sub-PI HRPP #131505